ALAnnika Lundström

Annika Lundström

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Annika Lundström has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Charlotte Thålin

    Division of Internal Medicine, Department of Clinical Sciences Karolinska Institutet Danderyd Hospital Stockholm Sweden

    4 shared publications
  • Per Sandén

    Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet (KI), Stockholm, Sweden

    3 shared publications
  • Fariborz Mobarrez

    Department of Medical Sciences, Uppsala University, Uppsala, Sweden

    2 shared publications
  • Fien von Meijenfeldt

    Surgical Research Laboratory, Department of Surgery University of Groningen, University Medical Center Groningen Groningen The Netherlands

    2 shared publications
  • Håkan Wallén

    Division of Cardiovascular Medicine, Department of Clinical Sciences, Danderyd University Hospital, Karolinska Institutet, Stockholm, Sweden

    2 shared publications
  • Louise Ziegler

    Division of Internal Medicine, Department of Clinical Sciences Karolinska Institutet Danderyd Hospital Stockholm Sweden

    2 shared publications

Latest Publications

  • Open Access

    Insights into Biomarker Correlations in Relation to Stress: A Preliminary Analysis

    by Annika Christina Lundstrom, Caterina Maria Sofia Mandalios

    The objective of this study was to analyze specific biomarkers of interest and find correlations between them using hormonal and cardiovascular measurements. The aim was to explore these physiological patterns during a typical weekday. While this research provides valuable insights into physiological patterns and their potential impact on mental performance, it’s essential to note that the study did not aim to diagnose, treat, or propose specific medical interventions based on the findings. Instead, the focus was solely on observational data collection and analysis for the purpose of exploring correlations and understanding daily physiological fluctuations in the context of stress and cognitive performance. Furthermore, the team observed how a low-level stress-triggered cognitive task could alter, and possibly impair, mental performance due to fluctuations in these selected data points. Five (5) adult, healthy participants (aged between 20 and 35 years) volunteered for the small-scaled study (two male and three female). In the current study, participants with larger hormonal and cardiovascular fluctuations during a 5-minute stress-induced task did not achieve as well as those with more stable physiological measurements. Interestingly, a significant peak in cortisol levels was detected during the mental task, likely due to the stress-induced environment. The current, and vastly limited methods used for at-home, hormonal measurements, as well as the slightly unreliable sensor technology used in general pulse oximeters measuring blood oxygen saturation in this trial, indicate the great need to develop new solutions. This includes innovations that would make health monitoring more convenient, while at the same time emphasizing improved mental well-being in daily situations, all without having to continuously wear a gadget to obtain precise insights about multiple health metrics.


  • Open Access

    Cerebral microvascular injuries in severe COVID-19 infection: progression of white matter hyperintensities post-infection

    by Ida Petersson, Bjorn M Hansen, Anders Svenningsson, Annika Lundstrom

    A range of neuroradiological findings has been reported in patients with COVID-19, some mimicking cerebral small vessel disease (CSVD). We present a case of a man in his 50s with severe COVID-19, who was Glasgow Coma Scale 3 and tetraparetic after sedation was ceased in the intensive care unit. Return of consciousness and motor activity was slow. An MRI 1 month after debut of symptoms demonstrated white matter hyperintensities on T2-weighted Fluid Attenuated Inversion Recovery (T2-FLAIR) and many small areas with impaired diffusion in primarily supratentorial and infratentorial white matter on Diffusion-Weighted Imaging (DWI). In the following months, the patient made a remarkable clinical recovery. Despite clinical improvement, an MRI after 7 months showed that white matter hyperintensities had progressed and become confluent. Both MRIs demonstrated findings resembling CSVD, which could relate to a COVID-19-specific process affecting cerebral microvasculature.


  • Open Access

    Editorial: Platelet Function in COVID-19

    by Annika Lundström, Per Sandén, Ioannis Mitroulis, Paola E. J. van der Meijden

    Editorial: Platelet Function in COVID-19


  • Open Access

    Soluble angiotensin‐converting enzyme 2 is transiently elevated in COVID‐19 and correlates with specific inflammatory and endothelial markers

    by Annika Lundström, Louise Ziegler, Sebastian Havervall, Ann‐Sofie Rudberg, Fien von Meijenfeldt, Ton Lisman, Nigel Mackman, Per Sandén, Charlotte Thålin

    The main entry receptor of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is angiotensin‐converting enzyme 2 (ACE2). SARS‐CoV‐2 interactions with ACE2 may increase ectodomain shedding but consequences for the renin‐angiotensin system and pathology in Coronavirus disease 2019 (COVID‐19) remain unclear. We measured soluble ACE2 (sACE2) and sACE levels by enzyme‐linked immunosorbent assay in 114 hospital‐treated COVID‐19 patients compared with 10 healthy controls; follow‐up samples after four months were analyzed for 58 patients. Associations between sACE2 respectively sACE and risk factors for severe COVID‐19, outcome, and inflammatory markers were investigated. Levels of sACE2 were higher in COVID‐19 patients than in healthy controls, median 5.0 (interquartile range 2.8–11.8) ng/ml versus 1.4 (1.1–1.6) ng/ml, p < .0001. sACE2 was higher in men than women but was not affected by other risk factors for severe COVID‐19. sACE2 decreased to 2.3 (1.6–3.9) ng/ml at follow‐up, p < .0001, but remained higher than in healthy controls, p = .012. sACE was marginally lower during COVID‐19 compared with at follow‐up, 57 (45–70) ng/ml versus 72 (52–87) ng/ml, p = .008. Levels of sACE2 and sACE did not differ depending on survival or disease severity. sACE2 during COVID‐19 correlated with von Willebrand factor, factor VIII and D‐dimer, while sACE correlated with interleukin 6, tumor necrosis factor α, and plasminogen activator inhibitor 1. Conclusions: sACE2 was transiently elevated in COVID‐19, likely due to increased shedding from infected cells. sACE2 and sACE during COVID‐19 differed in correlations with markers of inflammation and endothelial dysfunction, suggesting release from different cell types and/or vascular beds.


  • Open Access

    Soluble angiotensin-converting enzyme 2 is transiently elevated in COVID-19 and correlates with specific inflammatory and endothelial markers

    by Annika Lundström, Louise Ziegler, Sebastian Havervall, Ann-Sofie Rudberg, Fien von Meijenfeldt, Ton Lisman, Nigel Mackman, Per Sandén, Charlotte Thålin

    Rationale Angiotensin-converting enzyme 2 (ACE2) is the main entry receptor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but how SARS-CoV-2 interactions with ACE2 influences the renin-angiotensin system (RAS) in Coronavirus disease 2019 (COVID-19) is unknown. Objective To measure circulating ACE2 and ACE levels in COVID-19 patients and investigate association with risk factors, outcome and inflammatory markers. Methods and results Soluble ACE2 (sACE2) and sACE concentrations were measured by ELISA in plasma samples from 114 hospital-treated COVID-19 patients and 10 healthy controls. Follow-up samples after four months were available for 58/114 patients. Von Willebrand factor (VWF), factor VIII (fVIII), D-dimer, interleukin 6 (IL-6), tumor necrosis factor α and plasminogen activator inhibitor 1 (PAI-1) had previously been determined. Levels of sACE2 were higher in COVID-19 patients than in healthy controls, median 5.0 (interquartile range 2.8-11.8) ng/ml versus 1.4 (1.1-1.6) ng/ml, p < 0.0001. sACE2 was higher in men than women, but were not affected by other risk factors for severe COVID-19. sACE 2 decreased to 2.3 (1.6-3.9) ng/ml at follow-up, p < 0.0001, but remained higher than in healthy controls, p=0.012. Follow-up sACE2 levels were higher with increasing age, BMI, total number of comorbidities, for patients with diabetes and patients on RAS-inhibition. sACE was marginally lower during COVID-19 compared with at follow-up, 57 (45-70) ng/ml versus 72 (52-87) ng/ml, p=0.008. Levels of sACE2 and sACE did not differ depending on survival or disease severity (care level, respiratory support). sACE2 during COVID-19 correlated with VWF, fVIII and D-dimer, while sACE correlated with IL-6, TNFα and PAI-1. Conclusions sACE2 was transiently elevated in COVID-19, likely due to increased shedding from infected cells. sACE2 and sACE during COVID-19 differed distinctly in their correlations with markers of inflammation and endothelial dysfunction, suggesting release from different cell types and/or vascular beds.


  • High Thrombin Generation after Acute Ischemic Stroke or Transient Ischemic Attack Is Associated with a Reduced Risk of Recurrence: An Observational Cohort Study

    by Annika Lundström, Elisabeth Änggårdh-Rooth, Fariborz Mobarrez, Charlotte Thålin, Bruna Gigante, Ann Charlotte Laska, Håkan Wallén

    Thrombin is increasingly recognized to be of importance for cardiovascular disease. The aim of this study was to investigate the prognostic value of thrombin generation variables in a cohort of patients with acute ischemic stroke (AIS) or transient ischemic attack (TIA). Thrombin generation potential measured by calibrated automated thrombogram (CAT) and prothrombin fragment F1 + 2 was determined in the acute and convalescent phases for a cohort of 190 patients with AIS/TIA. Microvesicle (MV)-induced thrombin generation potential was determined for a subset of patients using modified CAT. Primary outcome was a composite of fatal and nonfatal AIS or myocardial infarction as documented in Swedish registers during a total follow-up of 986 patient-years. Hazard ratios (HRs) were calculated using Cox regression based on variable median split. Peak thrombin and endogenous thrombin potential (ETP) above median in the acute phase were associated with a reduced risk of primary outcome after adjustment for cardiovascular risk factors, HR: 0.50 (0.27–0.92), p = 0.026 and HR: 0.53 (0.28–0.99), p = 0.048, respectively. F1 + 2 was lower in patients than in healthy controls but not associated with outcome. MV-induced peak thrombin above median in the acute phase was associated with recurrent AIS, unadjusted HR: 2.65 (1.03–6.44), p = 0.044. Contrary to expectation, high thrombin generation potential is associated with a reduced risk of recurrent ischemic event in patients with AIS/TIA. Low ETP/peak thrombin combined with high MV-induced peak thrombin can potentially identify patients at high risk of recurrence.


  • Open Access

    Prognostic Value of Circulating Microvesicle Subpopulations in Ischemic Stroke and TIA

    by Annika Lundström, Fariborz Mobarrez, Elisabeth Rooth, Charlotte Thålin, Magnus von Arbin, Peter Henriksson, Bruna Gigante, Ann-Charlotte Laska, Håkan Wallén

    Platelet microvesicles (PMV) have previously been found elevated in acute ischemic stroke (IS) and could be biomarkers for risk of recurrence. PMV surface antigens such as P-selectin and phosphatidylserine (PS) reflect platelet activation and procoagulance. Tissue factor-positive microvesicles (TF+MV) are considered procoagulant, in particular if co-expressing PS. We enumerated MV subpopulations with these surface antigens in a cohort of 211 patients with primarily non-cardioembolic IS or transient ischemic attack (TIA) and investigated their association with long-term outcome. MV concentrations were determined by flow cytometry in the acute and convalescent phase. Primary outcome was a composite of fatal and non-fatal recurrent IS or myocardial infarction. Secondary outcomes were recurrent IS and all-cause mortality. Outcome events were obtained from Swedish registers during a follow-up of 1100 patient years. Concentrations of PS-positive and PS-negative MV populations were elevated in patients compared with healthy controls in both the acute and convalescent phase. PS+TF+PMV displayed pronounced elevations, median fold change 77 in the acute phase (p < 0.0001) but were not associated with outcome, neither were PS+P-selectin+PMV. The only subpopulation positively associated with primary outcome was PS−TF+PMV, with adjusted hazard ratio of 1.86 (1.04–3.31, p = 0.036) by Cox regression. Unexpectedly, several MV subpopulations tended to be associated with reduced risk of poor long-term outcome. Our results suggest that PS+TF+PMV may be a promising marker for cerebral ischemia, and that the in vivo generation of PS−MV after IS/TIA warrants further study. Future MV studies should ideally enumerate PS+ and PS−MV subpopulations separately.